With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...

The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...

Pharmaceutical giant GSK said on Monday that the US Food and Drug Administration has agreed to review its Biologics License ...

Investing.com -- The US Food and Drug Administration has accepted GlaxoSmithKline (NYSE: GSK )’s biologics license ...

Secondary endpoint analyses from the trials showed 'significant improvements' in patients treated with the antibody.

Depemokimab’s twice-yearly dosing regimen could offer a new approach to managing this chronic condition. With annual revenues of $39.28 billion and a steady dividend yield of 4.18%, GSK ...

GSK)’s biologics license application for depemokimab, a monoclonal antibody targeting interleukin-5 (IL-5), for regulatory review in two indications, GSK (LON:GSK) said in a statement on Monday.

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review the Biologics License Application, BLA, for the use of ...

An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial ...